Antide (acetate)
(Synonyms: N-((4R,7R,10R,13S,16S,19R)-19-(((S)-1-(((S)-1-((S)-2-((R)-1-氨基-1-氧代丙烷-2-基)氨基甲酰基)吡咯烷-1-基)-6-(异丙基氨基)-1-氧代己基-2-基)氨基)-4-甲基-1-氧代戊烷-2-基)氨基甲酰基)-7-(4-氯苄基)-13-(羟甲基)-4-(萘-2-基甲基)-16-(4-(烟酰胺基)丁基)-2,5,8,11,14,17-六氧代-10-(吡啶-3-基甲基)-3,6,9,12,15,18-六氮杂二十三烷-23-基)烟酰胺乙酸盐) 目录号 : GC46859A GnRHR antagonist
Cas No.:625092-10-6
Sample solution is provided at 25 µL, 10mM.
Antide is a third generation gonadotropin-releasing hormone receptor (GnRHR) antagonist.1,2,3,4 It inhibits GnRH-induced secretion of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and gonadotropin in isolated rat pituitary cells when used at concentrations ranging from 0.001 to 1,000 nM but does not induce histamine release in isolated rat mast cells (EC50 = >300 µg/ml).1,3 Antide (250 µg/kg, i.v.) reduces serum LH and FSH levels in orchidectomized cynomolgus monkeys.2 It inhibits ovulation in rats when administered at a dose of 2 µg/animal.3 Antide (10 µg/animal, s.c.) reduces the intensity and duration of catalepsy induced by haloperidol in rats.4
1.Danforth, D.R., Williams, R.F., Gordon, K., et al.Inhibition of pituitary gonadotropin secretion by the gonadotropin-releasing hormone antagonist antide. I. In vitro studies on mechanism of actionEndocrinology128(4)2036-2040(1991) 2.Weinbauer, G.F., and Nieschlag, E.Comparison of the antigonadotropic activity of three GnRH antagonists (Nal-Glu, Antide and Cetrorelix) in a non-human primate model (Macaca fascicularis)Andrologia25(3)141-147(1993) 3.Flouret, G., Arnold, Z.S., Majewski, T., et al.Antiovulatory antagonists of LHRH related to antideJ. Pept. Sci.1(2)89-108(1995) 4.Umathe, S.N., Wanjari, M.M., Manna, S.S.S., et al.A possible participation of gonadotropin-releasing hormone in the neuroleptic and cataleptic effect of haloperidolNeuropeptides43(3)251-257(2009)
Cas No. | 625092-10-6 | SDF | |
别名 | N-((4R,7R,10R,13S,16S,19R)-19-(((S)-1-(((S)-1-((S)-2-((R)-1-氨基-1-氧代丙烷-2-基)氨基甲酰基)吡咯烷-1-基)-6-(异丙基氨基)-1-氧代己基-2-基)氨基)-4-甲基-1-氧代戊烷-2-基)氨基甲酰基)-7-(4-氯苄基)-13-(羟甲基)-4-(萘-2-基甲基)-16-(4-(烟酰胺基)丁基)-2,5,8,11,14,17-六氧代-10-(吡啶-3-基甲基)-3,6,9,12,15,18-六氮杂二十三烷-23-基)烟酰胺乙酸盐 | ||
Canonical SMILES | ClC(C=C1)=CC=C1C[C@@H](NC([C@H](NC(C)=O)CC2=CC3=C(C=CC=C3)C=C2)=O)C(N[C@H](CC4=CN=CC=C4)C(N[C@@H](CO)C(N[C@@H](CCCCNC(C5=CN=CC=C5)=O)C(N[C@H](CCCCNC(C6=CN=CC=C6)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCNC(C)C)C(N7[C@@H](CCC7)C(N[C@H](C)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O.O=C(C)O | ||
分子式 | C82H108ClN17O14.C2H4O2 | 分子量 | 1651.3 |
溶解度 | DMSO: soluble,Ethanol: soluble | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.6056 mL | 3.0279 mL | 6.0558 mL |
5 mM | 0.1211 mL | 0.6056 mL | 1.2112 mL |
10 mM | 0.0606 mL | 0.3028 mL | 0.6056 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet